Parkinson’s disease does not hold still for an appointment. Symptoms shift hour by hour as medication takes hold and wears off, which means a neurologist’s twenty minutes with a patient captures one arbitrary slice of a moving picture, and the rest of it has to be reconstructed from memory. On October 28, the Boston- and Milan-based wearables company Empatica launched a product aimed squarely at that gap: WellPD, an FDA-cleared and CE-marked wrist-worn device and companion app that tracks Parkinson’s motor symptoms at home and hands the patient the data.
The notable part is not the sensor. It is who the data belongs to. Empatica’s underlying algorithms have been running inside hospitals for years. WellPD takes that clinical-grade measurement stack and sells it directly to the person wearing it.
What the device actually measures
According to Empatica’s launch announcement, the wrist unit tracks tremor, dyskinesia and bradykinesia, the three motor symptoms clinicians lean on most, along with sleep and physical activity. Sensors capture movement and other body signals; clinically validated algorithms convert those raw streams into symptom measures.
The product page adds a measure unique to WellPD, called WellMove, which reports how much of a given day the wearer spent with mild or no motor symptoms. That is a deliberately different framing from a symptom-severity score: it counts good hours rather than bad ones, which is closer to how patients describe their own days.
The app layer sits on top. Users log medication doses and receive reminders, and the system compiles daily, weekly and monthly summaries so patterns, say, disturbed sleep or a dip in movement at a consistent point after a dose, become visible without anyone keeping a paper diary. Empatica states plainly on its FAQ page that WellPD is intended to support a person’s understanding of their symptoms over time and does not replace a clinician’s assessment.
The hardware choices tell the story
Empatica says the wearable weighs 11 grams, roughly a pencil, uses a stretchable fabric band, is waterproof and runs 14 days on a charge. Each of those numbers is a decision about adherence rather than specification bragging.
A tremor-monitoring device that has to come off every night to charge misses sleep data, which is one of the measures the system is built to collect. One that is heavy or rigid gets abandoned by people whose hands are already difficult to work with. Fourteen days of battery life and a soft band are how you get continuous data from a population for whom fiddly interactions are the problem, not an inconvenience.
WellPD also includes its own wearable rather than running on a smartwatch. The company confirms on its FAQ that no Apple Watch or other smartwatch is required, though a compatible smartphone is, since the app receives data over Bluetooth and handles reminders and upload.
Where the algorithms came from
WellPD is not a from-scratch product. Empatica says it combines its own medical device engineering with the Parkinson’s expertise of PKG Health, which it acquired in 2025. The PKG algorithms, according to the company, are supported by more than 70 peer-reviewed publications and used in more than 150 hospitals and clinical sites worldwide, with pharmaceutical companies, universities and teaching hospitals using the technology to study disease progression, treatment response and digital endpoints in trials. Empatica’s figures also cite over 70,000 patients and 10 million hours of continuous monitoring behind the platform.
That acquisition is what makes this launch interesting rather than routine. The hard, slow, expensive part of a digital biomarker is validation: proving that a number produced by an accelerometer corresponds to something a trained neurologist would recognize. Empatica bought a validated measurement system and wrapped a consumer experience around it, instead of starting with the experience and hoping validation would follow.
What clinicians say it adds
Empatica’s announcement quotes Dr. Alessandro Di Rocco, neurologist and system director for Parkinson’s and Movement Disorders at Northwell Health, who frames the problem as one of complexity rather than available treatment: Parkinson’s is “one of the most common and treatable neurological disorders, yet its complexity often leads to suboptimal care.” His argument for wearables is that clinicians need to know how a patient sleeps, responds to treatment and manages symptoms at home, context that complements what the patient reports rather than replacing it.
Other clinicians quoted on the product page push the same point from different angles: Dr. Jesse Cedarbaum on measuring whether a treatment helps in everyday life rather than in a clinic visit, and neurology pharmacist Dr. Janine Barnes on the value of putting symptom tracking and medication logging in one place for people juggling multiple daily doses around meals.
Availability and the catch
WellPD is available to order now, with shipping starting November 23, according to the product page. Empatica lists availability in the United States, Canada, the United Kingdom, Australia, New Zealand, and in the European Economic Area: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Spain and Sweden. The pack includes the wearable, a charger and instructions for the app, and purchase involves choosing a subscription.
The US has one extra step: Empatica says WellPD requires a prescription from a US-based healthcare practitioner to ship to US territories, uploaded to the account after purchase rather than during it.
What it means
The direct-to-patient move is the thing to watch. Regulated measurement technology has generally reached patients through institutions, a clinician orders it, a clinic interprets it, and the patient receives a conclusion. WellPD inverts that: the patient buys the device, sees the measurements and brings them to the appointment.
That shift raises questions the launch does not answer. Subscription pricing on a medical wearable is a recurring cost in a condition that lasts decades. Reimbursement for patient-purchased monitoring remains uneven. And a clinician who receives months of continuous data from a patient has to find time to read it, which is its own workflow problem rather than a technical one.
For the broader digital health market, though, the pattern is worth noting: acquire a validated clinical algorithm, put consumer-grade industrial design around it, and sell to the person with the condition. Empatica has already run this play in epilepsy with EpiMonitor. Expect other companies holding validated measures in chronic disease to look hard at the same route.